Overexpression of the growth factor receptor subunit c-erbB2, leading to its ligand-independent homodimerization and activation, has been implicated in the pathogenesis of mammary carcinoma. Here, we have examined the effects of cerbB2 on the adhesive properties of a mammary epithelial cell line, HB2/tnz34, in which c-erbB2 homodimerization can be induced by means of a transfected hybrid 
INTRODUCTION
c-erbB2 is a member of the epidermal growth factor (EGF) receptor tyrosine kinase family and forms functional receptors for various growth factors (such as EGF and heregulin) by heterodimerization with other members of the same receptor family.
However, no ligand has been found that binds a c-erbB2 homodimer; instead, homodimerziation is thought to occur in a ligand-independent manner upon overexpression of c-erbB2. This phenomenon is of considerable interest in cancer research as a number of studies have linked c-erbB2 overexpression to poor prognosis in breast carcinomas (De Potter and Schelfhout, 1995) . Studies of forced c-erbB2 overexpression in animals and cell lines have demonstrated the oncogenic potential of c-erbB2, and spontaneous homodimerization leading to tyrosine kinase activation is most likely an important mechanism for the oncogenicity of cerbB2 overexpression (Weiner et al., 1989; Siegel and Muller, 1996) .
Since high constitutive overexpression of c-erbB2 in mammary epithelial cells can be associated with irreversible changes in cell phenotype, such as loss of epithelial characteristics and acquisition of anchorage-independent growth (D'Souza et al., 1993) , studies of the early phases in c-erbB2-induced cell transformation require an inducible system where c-erbB2 homodimerization can be regulated. Such a system has recently been developed (Baeckström et al., 2000) by transfecting the immortalized mammary epithelial cell line HB2 ) with a hybrid receptor construct, "trk-neu" (Sachs et al., 1996) consisting of the extracellular domain of the trkA nerve growth factor (NGF) receptor fused to the transmembrane and cytoplasmic domains of c-erbB2. By treating these transfectants with NGF, the intracellular effects of c-erbB2 homodimerization can be simulated, leading to tyrosine kinase activation and substrate domain phosphorylation. In HB2 transfectants expressing high levels of the trk-neu hybrid, NGF-induced homodimerization resulted in a dramatic disruption of morphogenesis of cells grown in 3-dimensional culture in collagen, causing cells to grow in a scattered fashion as opposed to the multicellular, compact and spherical morphology of untreated transfectants and parental HB2 cells (Baeckström et al., 2000) . The disrupted morphology of NGF-treated transfectants, which was accompanied by decreased proliferation and extensive apoptosis, could be completely restored by treatment with antibodies that activate the collagenbinding integrin α 2 β 1 , indicating that the morphogenetic effects of c-erbB2 signaling occur by integrin inactivation.
In order to dissect the intracellular signaling mechanisms leading from c-erbB2 homodimerization to inhibition of integrin-dependent morphogenesis, a more rapid and tractable assay for integrin function and morphogenesis than 3-dimensional culture is desirable. In the present study, we have instead used c- 
cDNA constructs
The expression plasmids used in this study were gifts generously provided by the following researchers: pMT2/ILK, pMT2/ILK(K220M) and pMT2/ILK(S343D) containing cDNA coding for wild-type, dominant-negative and activated integrinlinked kinase (ILK), respectively, were from Dr. Ian Hiles, GlaxoWellcome, United Kingdom; pCMV5.SNE/PKBα and pCMV5.SNE/PKBα(K179A) used for expression of HA-tagged wild-type and dominant-negative PKBα, respectively, were from Dr. Brian A Hemmings, Friedrich Miescher Institut, Zürich, Switzerland; pCEP4/PTEN coding for wild-type PTEN phosphatase was from Dr.
Ramon Parsons, Columbia University, New York; and pECE/HA-MEK1-ca, coding for a constitutively active mutant (S218D/S222D) of hamster MEK1 (Pages et al., 1994) , was a gift from Pär Gerwins, Rudbeck Laboratory, University of Upsala, Sweden. The reporter plasmids pCMVβ and pEGFP-C1 coding for LacZ and green fluorescent protein (GFP), respectively, were from Clontech. Plasmids were propagated in appropriate E. coli strains and purified using the JetStar plasmid purification system (Genomed).
Cell culture
The HB2/tnz34 cell line, (Baeckström et al., 2000) a high-expressing trk-neu transfectant derived from the SV40-immortalized human mammary epithelial cell line HB2 , was grown in Dulbecco's modified Eagle's medium (DMEM, Life Technologies) supplemented with 10% fetal calf serum (FCS) 5 µg/ml hydrocortisone, 10 µg/ml insulin and 5 µg/ml zeocin (Invitrogen).
Inhibitor treatments
All pharmacological inhibitors were administered as stock solutions in dimethyl sulfoxide (DMSO) and control cells were given the corresponding amount of pure DMSO. Inhibitor concentrations were generally chosen in the range of 5-10 times the IC 50 value supplied by the manufacturer. Different concentrations were always tested in order to rule out over-or underdosage effects.
Spreading assays
Thin (approx. 150 µm) layers of polymerized collagen I were prepared by smearing 100 µl of neutralized collagen I over the surface of the wells of 6-well plates (prior to the application of collagen, the edges of the wells had been prepared with sterilized vacuum grease to prevent accumulation of liquid at the well periphery). After polymerization for 2 h at 37 °C, 1-2x10 4 HB2/tnz34 cells were plated as a single-cell suspension in 2 ml complete medium/well and incubated for 2 days. The cells were then transfected in situ (see below) or subjected to treatments with NGF (10 ng/ml) and/or inhibitors for an additional 1-2 days before fixation with 2% formaldehyde and 0.2% glutardialdehyde in PBS.
Spreading was evaluated in untransfected cells by visual inspection of two 4x-magnification videomicrographs/sample where cells were scored either as "round" (more than 50% of the cell periphery visible as a sharp edge) or "spread"
(more than 50% diffuse cell boundary 
Transfections
For analysis of transfected cells in spreading assays, transient transfections of HB2/tnz34 cells growing on collagen were performed as follows: For each well, 1 µl of DMRIE-C reagent was mixed and incubated for 30 min. with 100 µl serumfree medium before the addition of another 100 µl serumfree medium containing a total of 1.5 µg plasmid DNA (0.75 µg plasmid containing gene of interest and 0.75 µg of the LacZ expression vector pCMVβ (Clontech); control samples were transfected with 1.5 µg of pCMVβ only). The transfection mixture was kept for another 15 min. at room temperature before transferring 200 µl to each well (wells were washed with serumfree medium prior to transfection). After incubation for 5 h in CO 2 incubator, the transfection mixture was removed, wells were washed once with serum-containing medium and kept overnight with serum-containing medium before incucubation with or without NGF.
In order to prepare transiently transfected cells for use in the adhesion assays, polyethyieneimine transfections were employed. For one 6-cm tissue culture dish, a total of 6 µg plasmid DNA was added to 6 µl 20% glucose solution and this mixture was then added to 5 µl 0.1 M polethyleneimine solution, buffered to pH 7.0. After thorough mixing, deionized water was added to 60 µl and the mixture was left for 10 min. at room temperature. This solution was then mixed with 4 ml fresh complete, serum-containing cell culture medium and added to HB2/tnz34 cells grown to 60-70% confluence. The cells were then kept with the DNA-PEI complex-containing medium for two days before being detached and subjected to adhesion assay.
Adhesion assays
96-well microtiter plates were coated with monomeric collagen by dispensing
Vitrogen 100 serially diluted (10 -0.005 µg/ml) in 10 mM HCl at 50 µl/well and incubating over night at +4 °C. Plates were then blocked by incubation with 100 µl/well of PBS containing 0.1% heat-treated BSA at 37 °C for 1 h. Subconfluent cultures of HB2/tnz34 cells were detached by incubation with Puck's saline containing 0.02% EDTA, mixed with an equal volume of serum-containing medium and passed through a 23-gauge needle in order to create a single-cell suspension. Cells were then washed in serum-free medium and resuspended at a density of 2.5*10 5 /ml in serum-free medium with 5 mM MgCl 2 . The cells were then pre-treated with antibodies or inhibitors (where applicable) for 1 h before addition of NGF (standard concentration: 50 ng/ml) where applicable, followed by another 1-h incubation (both incubation steps were performed at room temperature). 100 µl cell suspension was then dispensed in each well of the coated microtiter plates and the plates were left in the incubator for 1 h. Non-adherent cells were then removed by inversion and flicking of plates followed by washing 3 times by immersion of the plate in PBS containing 5 mM MgCl 2 and aspiration of buffer by water suction connected to a 21-gague needle. The amount of adherent cells was quantitated by crystal violet staining following fixation with 4%
formaldehyde as described (Wu et al., 1999) . 
Western blots
Lysates of HB2/tnz34 cells growing on plastic were prepared from subconfluent cultures grown on 60-mm cell culture dishes. Cells were washed 3 times with PBS and lysed in 50 mM tris-HCl, pH 7.5, 0.15 M NaCl, 1% Triton X-100 containing protease inhibitor cocktail (Sigma) supplemented with 10 mM sodium pyrophosphate, 1 mM sodium orthovanadate and 10 mM NaF. Following protein concentration determination (BCA assay, Pierce), normalized protein amounts were loaded onto SDS-PAGE gels, separated and blotted to PVDF membranes 
RESULTS

Induced c-erbB2 homodimerization inhibits spreading and adhesion of mammary epithelial cells on collagen
HB2/tnz34 is a high-expressing trk-neu transfectant of the mammary epithelial cell line HB2 that exhibits a striking disruption of integrin-dependent morphogenesis upon c-erbB2 homodimer signaling induced by NGF treatment when grown in a 3-dimensional collagen matrix (Baeckström et al., 2000) . In order to understand the molecular mechanism behind this observation, we wished to identify the intracellular events that link c-erbB2 homodimer signaling with inhibition of morphogenesis. Since the morphogenesis assay used in the previous study requires that cells survive and proliferate for approximately one week, we wished to develop an assay for integrin-dependent morphogenesis that was faster and thus more amenable to pharmacological and genetic manipulation than 3-dimensional culture. Therefore, we chose to study spreading on collagen as a simplified morphogenesis assay. In the absence of c-erbB2 signaling, HB2/tnz34 cells spread on a polymerized collagen surface, typically reaching 75% flat cells after 3 days; however, NGF treatment strongly inhibited this spreading in a dosedependent manner (Figure 1 A and B) . By adding NGF to the cells at different time points during a 72-h incubation, we could conclude that the suppressing effect of c-erbB2 signaling on spreading reached a plateau after approximately 24 h of induction ( Figure 1C ).
It has also previously been shown that the disruption of morphogenesis in collagen caused by c-erbB2 could be reversed by treatment with antibodies that activate β 1 or α 2 integrins (Baeckström et al., 2000) . Since this result indicated that the morphogenetic disruption seen in NGF-activated HB2/tnz34 cells is caused by integrin inactivation, it was of interest to directly assess the possible influence of cerbB2 on integrin function. To that end, we measured the capacity of untreated and NGF-treated HB2/tnz34 cells in suspension to adhere to monomeric collagen coated in serial dilutions in microtiter wells. As shown in Figure 2A , adhesion was indistinguishable (approximately 70% cells bound, data not shown) between controls and NGF-treated cells at high collagen densities (500 ng/well); however, under conditions where collagen was limiting, a pronounced, dose-dependent suppression of adhesion was observed upon NGF treatment ( Figure 2A ). In order to be able to compare large and complex sets of data, the results of the adhesion assays in the rest of this paper are presented as the amount of coated collagen required for half-maximal binding (ED 50 , see "Materials and Methods" for details on calculation); as an example, the ED 50 values corresponding to the data from Figure 2A are presented in Figure 2B , plotted against the NGF concentration. From these figures, it can be seen that the c-erbB2-induced inhibition of adhesion reached a plateau at NGF doses at or above 50 ng/ml, where the ED 50 value typically was 10 times higher than in NGF-untreated cells (fold-increase averaged over 40 assays = 9.86).
Using an accelerated adhesion assay (where cells were briefly centrifuged to avoid the time delay required for sedimentation), we could observe inhibition of adhesion after a minimum of 30 minutes of c-erbB2 signaling, reaching maximum level after 1 h ( Figure 2C ). As expected for such a rapid response, c-erbB2-induced adhesion downregulation was independent of both transcription and protein Adhesion to collagen of HB2/tnz34 cells is mediated by integrin α 2 β 1 , the function but not surface abundance of which is affected by c-erbB2
We next wished to identify the specific integrin(s) of importance for the binding of HB2/tnz34 cells to collagen in our adhesion assay. Cells were therefore pretreated with blocking antibodies to the collagen-binding integrin subunits α 1 , α 2 and α 3 and their heterodimerization partner β 1 before analyzing the adhesion to collagen. As shown in Figure 3A , adhesion was strongly suppressed by antibodies against the α 2 and β 1 subunits whereas inhibition of α 1 -which is poorly expressed in these cells and unpublished results) -or α 3 had no effect on adhesion. We thus concluded that the main integrin responsible for collagen binding under these conditions was α 2 β 1 .
Our results indicated that the ability of integrin α 2 β 1 to bind collagen was suppressed by c-erbB2 homodimer signaling. One possible mechanism for this event would be that c-erbB2 signaling causes a depletion of the integrin from the cell surface. In order to test this hypothesis, HB2/tnz34 cells were left in suspension for 1 h with or without NGF (conditions identical to those used in the adhesion assays) and then subjected to FACS analysis using antibodies against the α 2 and β 1 subunits. The results showed that no change in surface expression of these integrin subunits could be detected upon NGF treatment ( Figure 3B ). It thus appeared that the effect of c-erbB2 on the α 2 β 1 integrin was mediated by a modulation of integrin function rather than abundance. We assessed this possibility by treating the cells with the monoclonal antibodies TS2/16 which activates the binding capacity of β 1 integrins and JBS2 which specifically stimulates integrin α 2 β 1 , prior to NGF treatment and adhesion assay. We found that both antibodies almost completely restored adhesion in the presence of cerbB2 signaling ( Figure 3C ). The anti-α 2 antibody HAS4 (Tenchini et al., 1993) , for which a stimulatory role also has been suggested (Alford et al., 1998; Baeckström et al., 2000) , had a similar effect. We therefore concluded that the major cause of cerbB2-induced suppression of adhesion to collagen is functional inhibition of integrin α 2 β 1 .
Although the function of the integrin-stimulating antibodies is generally held to be caused by induction of conformational changes in the extracellular domain, it cannot be concluded that c-erbB2-induced suppression of adhesion also affects integrin conformation. Another possible mode of integrin suppression is by weakening integrin-cytoskeleton interactions, which are essential for integrin
function. In order to analyze this possibity, we treated HB2/tnz34 cells with the actin-depolymerizing drug cytochalasin D. While adhesion was completely abolished at higher concentrations (100 nM, not shown), a concentration of 10 nM caused a suppression of adhesion similar to NGF treatment, and addition of NGF to these cells did not significantly affect adhesion further ( Figure 3D ). The TS2/16
antibody could however still restore adhesion in cytochalasin D-treated cells.
These data indicate that the effect of c-erbB2 on integrin function is dependent on the integrity of the actin cytoskeleton and suggest that the integrin-cytoskeleton linkage may be affected by c-erbB2.
c-erbB2-induced integrin inhibition is dependent on the MEK1/2 MAP kinase pathway
Next, we wished to determine the intracellular signaling pathways involved in mediating the antagonistic effects of c-erbB2 signaling on the function of integrin α 2 β 1 . We reasoned that if such a signaling pathway could be blocked, then the trkneu transfected cells would adhere normally even upon c-erbB2 homodimer signaling. Furthermore, the importance of the pathways studied for integrinregulated morphogenesis could also be assessed by comparing with the effects of the same treatment in the spreading assay. We therefore studied the effects of interference with the function of intracellular signaling enzymes using pharmacological inhibitors and transient transfections.
Since a Ras/Raf-initiated pathway, leading to the activation of the MAP kinases ERK1/2 has previously been implicated in integrin inactivation (Hughes et al., 1997) , and since the EGF receptor family tyrosine kinases are known to activate Ras, it was of interest to study the role of this pathway in c-erbB2-induced inhibition of adhesion and spreading. Using western blot with antibodies specific for the activated, phosphorylated state of ERK1/2, we could confirm that this pathway is indeed activated by the c-erbB2 homodimer in HB2/tnz34 cells ( Figure   4A ). The importance of ERK activation in integrin regulation by c-erbB2 was then analyzed by treating HB2/tnz34 cells with NGF in combination with PD98059, which inhibits the activation of the MAP kinase kinases MEK1 and MEK2, immediate upstream activators of ERK1/2. As shown in Figure 4B , treatment with PD98059 resulted in restoration of adhesion and spreading in NGF-treated HB2/tnz34 cells. These results indicate that activation of a MEK-ERK pathway is required for inactivation of integrin α 2 β 1 by c-erbB2 and suggest that this effect is important for disruption of spreading morphogenesis.
Activation of phospoinositide-3-kinase-dependent pathway(s) is also required for c-erbB2-induced integrin inactivation
Although our results supported the notion that the MEK1/2 pathway is required for integrin inactivation, they did not exclude the possibility that other intracellular signals are equally important for this process. Phospoinositide-3-kinase (PI3K) is another major effector of receptor tyrosine kinases which regulates a number of pathways of crucial importance to a variety of cellular functions. We could readily detect c-erbB2-induced activation of PI3K in HB2/tnz34 cells by measuring the activating phosphorylations at Thr308 and Ser473 in protein kinase B (PKB), a well-established PI3K effector, upon NGF treatment ( Figure 5A ). The PI3K-dependence of this event was verified by the abrogating effect on PKB phosphorylation of treatment with LY294002 and wortmannin, two pharmacolgical PI3K inhibitors. In order to investigate a possible role of PI3K in integrin regulation by c-erbB2, we used these two PI3K inhibitors in our adhesion and spreading assays. While wortmannin completely restored primary adhesion to collagen in NGF-treated HB2/tnz34 cells ( Figure   5B ), LY294002 was without effect under standard conditions for this assay (1h of inhibitor treatment followed by addition of NGF). Intriguingly, spreading of these cells was restored by LY294002 but not wortmannin. Wortmannin is known to be more unstable than LY294002; however, repeated additions of fresh wortmannin during the 24-h incubation with NGF also failed to restore spreading. We asked ourselves whether the difference in response to LY294002 between the spreading and adhesion readouts could be due to the difference in the duration of the assays (2 h in adhesion assay vs. 24 h in spreading assays). We therefore studied the influence of LY294002 on the adhesion of cells that had been pre-treated with NGF for 24 h. Under these conditions, adhesion was indeed restored ( Figure 5B) . It thus appears that the sensitivity to LY294002 of the integrin-regulating PI3K response varies with the duration of the c-erbB2 signaling. Long-term NGF treatment did however not change the effect of LY294002 or wortmannin on NGF-induced activating PKB phosphorylation as compared to the short-term conditions shown in Figure 5A (data not shown).
As an alternative to the PI3K inhibitor treatments, we also examined the effect of overexpressing the phosphoinositide-3-phosphatase PTEN, which antagonizes PI3K function by lowering the intracellular levels of 3-phosphoinositides. Methods" for details). Using this technique, we found that PTEN could restore integrin function both in spreading and adhesion assays ( Figure 5C ). We therefore tentatively concluded that PI3K is required for integrin inactivation by c-erbB2 but that the dependence is likely to be complex, with different downstream components showing differences in influence on adhesion, sensitivity to inhibitors and in dependence on signal duration.
Protein kinase B and integrin-linked kinase mediate integrin regulation downstream of PI3K
In order to resolve the question of the possible importance of PI3K-dependent pathways in c-erbB2-induced integrin inactivation, we sought to interfere with the function of individual PI3K effectors and study the resulting effect on adhesion and spreading. We had already established that PKB was activated by c-erbB2 in our system ( Figure 5A ). PKB is a major mediator of PI3K signaling which has been implicated in diverse biological phenomena such as metabolic control, protection against apoptosis, and cell motility (Chan et al., 1999; Kim, 2001) . In addition to its requirement for direct binding to 3-phosphoinositides, activation of PKB is also dependent on the upstream activators phosphoinositide-dependent kinase (PDK-1) and, interestingly, the integrin-linked kinase (ILK), a putative serine/threonine kinase which also binds the β 1 integrin, promoting its phosphorylation and functional downregulation (Hannigan et al., 1996) . In order to elucidate whether cerbB2-induced integrin inactivation is dependent on PKB and/or ILK, we transiently transfected wild-type and dominant-negative PKB and ILK constructs into HB2/tnz34 cells and studied the behaviour of transfected cells in adhesion and spreading assays. The results of these assays showed a striking restoration of adhesion and spreading by dominant-negative PKB and ILK in NGF-treated HB2/tnz34 cells ( Figure 6A-B) . Indeed, overexpression of wild-type PKB was sufficient to suppress adhesion in the absence of NGF. In contrast, wild-type ILK transfection did not alter adhesion or spreading (data not shown).
Since the adhesion-suppressing response of PKB transfection (measured as ED 50 value) was more than 5 times stronger than that of NGF-induced c-erbB2 signaling and since the duration of elevated PKB signaling by necessity was much longer following PKB transfection than the standard 1-h NGF treatment, we asked whether some other mechanism than integrin inactivation might be involved in this effect. We therefore analyzed the effect of PKB overexpression on the levels of integrin α 2 and β 1 surface expression in flow cytometry, using co-expressed GFP as a reporter for transfection. In this assay, integrin levels were unaffected by PKB (shown for α 2 in Figure 6D ; identical results were obtained in similar experiments
where the other constructs used in this study were expressed (data not shown)).
Moreover, when PKB-transfected cells were treated with the integrin-activating antibody TS2/16, adhesion was restored by more than 95% (see Figure 8A ), strongly indicating that integrin inactivation indeed is the major mediator of the anti-adhesive effect of PKB. These results demonstrate a novel role for PKB as a potent regulator of the functional status of integrins and as a mediator of the antiadhesive and anti-morphogenetic effects of strong c-erbB2 homodimer signaling.
c-erbB2 activates a PKB-independent, rapamycin-sensitive pathway that is required for inhibition of adhesion but not spreading
The complex response of c-erbB2-induced integrin inactivation to PI3K inhibitors prompted us to search for additional PI3K effectors that might mediate this effect apart from, or maybe as an effector of, PKB. Since treatment with inhibitors against protein kinases A or C (which both are activated by PDK-1 (Cantrell, 2001) ) was unable to restore spreading or adhesion in NGF-treated HB2/tnz34 cells (Table 1) , these signaling molecules are unlikely to play an important role in integrin regulation by c-erbB2 .
The p70 S6 kinase (S6K) is also reported to be indirectly activated by PI3K in a PDK-1-and possibly also PKB-dependent manner (Dufner and Thomas, 1999) .
Activating phosphorylation of S6K was found to be induced by c-erbB2
homodimer signaling in a manner sensitive to inhibition of PI3K but not of MEK ( Figure 7A ). We therefore analyzed the influence on c-erbB2-induced integrin inactivation of rapamycin, which inhibits activation of S6K by the upstream kinase mTOR. As shown in Figure 7B , rapamycin potently restored primary adhesion, but not spreading in NGF-treated HB2/tnz34 cells. S6K or some other mTOR effector is therefore likely to be a necessary mediator of the anti-adhesive effect of PI3K. The mTOR/S6K pathway has mainly been implicated in selective regulation of protein synthesis (Gingras et al., 2001) . Since c-erbB2-induced integrin inactivation was shown to be independent of protein synthesis ( Figure 2D ), our results suggest a novel mode of function for S6K -or some other mTOR effectorin integrin regulation.
Some studies have suggested a role for PKB in activation of the mTOR-S6K pathway, although this connection has been disputed (Dufner and Thomas, 1999) .
We analyzed a possible link between PKB and mTOR-S6K in c-erbB2-induced integrin regulation by treating PKB-transfected HB2/tnz34 cells with rapamycin in adhesion assays. As shown in Figure 7C , the suppression of adhesion caused by PKB was completely unaffected by rapamycin treatment, indicating that PKB and the rapamycin-sensitive pathway act as parallel and independent mediators of the integrin-inactivating effect of PI3K. This conclusion was further strengthened by the observed lack of S6K activation upon PKB transfection (data not shown).
The MEK and PKB pathways appear to regulate integrin activity via common target(s)
The reversal of c-erbB2-induced disruption of adhesion and spreading observed when the function of either MEK or PKB was inhibited strongly indicated that both signaling pathways were required for integrin inactivation by c-erbB2. It was therefore somewhat surprising that suppression of integrin function could be achieved solely by overexpression of PKB in the absence of c-erbB2 homodimer signaling ( Figure 6A ). First, in order to test the possibility that PI3K or PKB could activate MEK, we searched for evidence of cross-talk between these pathways by using inhibitor treatments, transfections or combinations of both. As shown in Table 2 , no manipulation of the PI3K or PKB pathways had any effect on ERK phosphorylation and conversely, neither activated MEK1 nor the MEK inhibitor PD98059 could influence the activation status of PKB (in addition, we showed that the rapamycin-sensitive pathway also is independent of the MEK pathway). These results clearly indicated that the MEK and PKB pathways were acting in a parallel fashion. Another possible explanation for the apparent MEK-independence of the effect of PKB on adhesion would be that the constitutive MEK activity in unstimulated cells was sufficient to support integrin inactivation when combined with increased PKB activity. However, when we inhibited MEK signaling by treatment with PD98059, the integrin-inactivating effect of PKB overexpression was not diminished ( Figure 8A) . Thus it appears that PKB, when expressed at a sufficiently high level, can mediate integrin inactivation in the absence of MEK activity. This in turn suggests that the MEK and PKB pathways may employ common downstream targets for regulating integrin activity. Such a hypothesis would predict that stimulation of the MEK pathway in the absence of PKB signaling also would be sufficient for integrin inactivation. As shown in Figure 8B , transient transfection with constitutively active MEK1 was indeed capable of suppressing adhesion in the absence of NGF-induced c-erbB2 homodimer signaling, an effect which was not perturbed by co-transfection with dominantnegative PKB. The suppressive effect of MEK transfection appeared considerably weaker than that induced by PKB; however, this discrepancy may be explained by the higher degree of overexpression of PKB compared to MEK (Fig. 8C ) although it should be kept in mind that the the MEK used was a constitutively active mutant whereas PKB was wild-type. We also confirmed that the adhesionsuppressing effect of MEK1 transfection could be reversed by integrin activation mediated by treatment with the TS2/16 mAb ( Figure 8B) . It therefore appears that overexpression of either PKB or MEK1 overrides the requirement for activation of both pathways in order to achieve integrin inactivation. These results are thus in accordance with the hypothesis that the MEK and PKB pathways may use common downstream effectors for downregulation of integrin function.
DISCUSSION
The present study was prompted by the profound effect of intense c-erbB2
homodimer signaling on morphogenesis of mammary epithelial cells in 3-dimensional collagen culture and its reversal by integrin activation observed previously (Baeckström et al., 2000) . Here, we have attempted to elucidate the intracellular events that mediate this morphogenetic effect. Adhesion assays have been employed in order to study the regulation of integrin function without interference from other phenomena, whereas spreading assays were used as a simplified indicator of morphogenesis. Our findings can be summarized as follows:
(i) Integrin function is negatively affected by c-erbB2. This was suspected from the earlier finding that the inhibition of morphogenesis in collagen caused by c-erbB2
homodimer signaling could be reversed by antibodies that activate α 2 or β 1 integrins (Baeckström et al., 2000) . However, the present study provides direct evidence that c-erbB2 inhibits integrin-dependent matrix adhesion. Specifically, we have shown that primary adhesion to collagen of HB2/tnz34 cells is dependent on integrin β 1 and α 2 subunits and that c-erbB2-induced inhibition of adhesion can be completely reversed by monoclonal antibodies that induce an active conformation in the α 2 β 1 integrin. Moreover, the restoration of adhesion caused by inhibitor treatments (discussed below) was consistently abrogated by incubation with an α 2 -blocking antibody, and in no case did these inhibitors cause increased surface expression of integrin α 2 or β 1 (data not shown). Together these findings strongly indicate that the function of integrin α 2 β 1 is suppressed by c-erbB2 and that the manipulations that restore adhesion do so by relieving this suppression.
Integrin function can be regulated by changing integrin extracellular conformation, clustering of integrins at the cell surface or integrin-cytoskeletal attachment. The present study cannot conclusively identify at what level(s) the anti-adhesive signal from c-erbB2 acts. However, since no effect of NGF was seen in the cytochalasin D-treated cells ( Figure 3D ), it is highly likely that a cytoskeleton-dependent mechanism plays an important role. Detection of changes in β 1 extracellular conformation using activation epitope-specific antibodies has been attempted (data not shown), but although a reproducibly suppressive effect of NGF could be seen, the interpretation of these results was hampered by the very weak binding of the conformation-specific antibodies to untreated as well as manganese-activated cells. It is possible that the regulation of β 1 integrin activity in epithelial cells involves more subtle changes in extracellular conformation.
( clearly indicate that regulation of transcription or protein synthesis is not involved. We have also established that the effect of PD98059 (as well as that of the other adhesion-restoring inhibitors wortmannin and rapamycin) was insensitive to cycloheximide treatment (data not shown). As will be discussed below, our data suggest that the ERK signal and those of other pathways may target a common integrin-regulating effector.
In our initial characterization of the possible PI3K-dependence of c-erbB2-induced inhibition of adhesion and spreading using the two widely employed pharmacological PI3K inhibitors LY294002 and wortmannin, the paradoxical result was obtained that adhesion was restored by wortmannin but not LY294002, whereas the reverse was the case for cell spreading ( Figure 5B ). In the case of LY294002, a time-dependent effect is suggested by the observation that following prolonged (24 h) c-erbB2 activation, the adhesion-suppressing response of HB2/tnz34 cells becomes sensitive to LY294002 although the duration of the inhibitor treatment is not changed. Since overexpression of the 3-phosphoinositide phosphatase PTEN as well as inhibition of at least two different PI3K effectors also restored integrin function (see below), we feel that it is safe to conclude that cerbB2-induced integrin inactivation indeed is PI3K-dependent. As a tentative explanation for the difference in response to PI3K inhibitors observed, one may speculate that PI3K elicits integrin-activating as well as integrin-inactivating mechanisms and that the balance between opposing effects on integrin function downstream of PI3K may be sensitive to how PI3K is inhibited and/or to the duration of the PI3K signal. The slight difference in inhibition efficiency beteween LY294002 and wortmannin seen in Figure 5A may be of importance in this context. Different PI3K effectors have previously been reported to respond differently to LY294002 compared to wortmannin (Adi et al., 2001) . Although wortmannin is known to be capable of inhibiting myosin light chain kinase (Nakanishi et al., 1992) and the mammalian target of rapamycin (mTOR) (Gingras et al., 2001 ) in addition to PI3K, these kinases are not likely to be direct mediators of the effect of wortmannin in our experiments, since the concentrations required for their inhibition (≈ 200 nM) are far higher than the 25 nM used in our adhesion assays .
While PI3K has often been implicated in downstream events following integrinligand binding, only a small number of reports describe a role for PI3K in the regulation of integrin function (e.g. (Shimizu et al., 1995; Zhang et al., 1996) ); moreover, in those studies PI3K was found to enhance integrin-mediated matrix adhesion. Likewise, the morphogenetic effects of PTEN overexpression have earlier been described by Tamura et al. as antagonistic to spreading (Tamura et al., 1998) . These observations are thus in apparent conflict with our data, which indicate that integrin function is inhibited by PI3K and restored by PTEN. It should however be kept in mind that whereas the cells used by Tamura PKB has often been implicated in events following integrin engagement (outsidein signaling, e.g. (Khwaja et al., 1997) ); however, this is to our knowledge the first report of a crucial role for PKB in cellular regulation of integrin function (insideout signaling). Interestingly, PKB has recently been implicated in cancer cell motility and invasion (Kim, 2001 ). This effect was partly explained by increased metalloproteinase production, and no changes in primary adhesion to collagen were observed upon PKB transfection. However, only one relatively high collagen coating concentration was used in the adhesion assays and, as shown in the present study, suppression of adhesion due to integrin inactivation may not be evident under conditions where the supply of matrix is not limiting. Another recent report (Kirk et al., 2000) has demonstrated phosphorylation of integrin β 3 at a cytoplasmic threonine by PKB; however, the report did not investigate possible changes in the functional status of the integrin following this event. The threonine residue in question is situated in a region which is conserved between β integrins and it is a possibility worth exploring that a similar event is taking place in β 1 integrins upon c-erbB2-induced activation of PKB and that this contributes to integrin inactivation.
Our data also identify ILK as a necessary mediator of the integrin-inactivating effects of c-erbB2. While ILK was initially identified as a molecule that binds, phosphorylates and inactivates integrin β 1 (Hannigan et al., 1996) , very little is known about this aspect of ILK function. Instead, the bulk of our present knowledge about ILK pertains to its role in activating downstream effectors such as PKB, glycogen synthase kinase-3 and the β-catenin pathway (Delcommenne et al., 1998; Tan et al., 2001) . However, in HB2/tnz34 cells, neither downregulation of adhesion nor PKB phosphorylation could be observed following overexpression of either wild-type ILK or a putatively activated S343D mutant (Lynch et al., 1999) (data not shown). It is therefore possible that these effects of ILK are cell-type dependent or that higher expression levels of ILK than those achieved in the present study are required to suppress adhesion and/or cause PKB phosphorylation in HB2/tnz34 cells. These observations, and the finding that PKB is capable of causing integrin inactivation, raise the intriguing possibility that downregulation of matrix adhesion by ILK (Hannigan et al., 1996) is mediated by PKB. One may speculate that ILK recruits PKB to the vicinity of integrin cytoplasmic domains, where PKB becomes activated and phosphorylates the integrins or associated proteins necessary for integrin function. Since ILK has been shown to have a vital function in Drosophila that is independent of its kinase activity (Zervas et al., 2001) , one may speculate that ILK regulates integrin function both as a kinase-independent adapter molecule and, maybe more subtly, as an integrin-proximal activator of PKB.
The surprising result that c-erbB2-induced inhibition of adhesion can be reversed by treatment with rapamycin indicates a previously unknown function for the protein kinase mTOR (mammalian target of rapamycin), which has mainly been known as a specific regulator of protein synthesis (Gingras et al., 2001) . The most well-described effector of mTOR is S6K, a protein kinase known to phosphorylate the S6 ribosomal protein, thereby mediating a major part of the translationregulating function of mTOR (Proud, 1996) . Neither kinase has earlier been implicated in regulation of cell adhesion. Since S6K but not mTOR is reported to be dependent on PI3K for activation (Gingras et al., 2001) , it is possible that the observed rapamycin-sensitive suppression of adhesion is mediated by activation of S6K by PI3K and that mTOR itself plays a permissive role. On the basis of the present data, it is however not possible to decide whether it is S6K or some other mTOR effector that is mediating integrin inhibition. In either case, this pathway is likely to be acting in parallel with and not downstream of PKB, since rapamycin was unable to restore the suppression of adhesion caused by transfection with wild-type PKB; in addition, PKB overexpression failed to induce activating phosphorylation of S6K (data not shown). In contrast to these data, an interesting recent report (Neshat et al., 2001) pathways that were shown to be important for adhesion also affected spreading.
This correlation suggests that the mechanisms that govern the rapid modulation of integrin activation status also are critical to the more long-term effects of c-erbB2 on cellular morphogenesis. Such a conclusion strengthens the concept of a crucial role for integrin regulation in c-erbB2-induced conversion of cellular phenotype.
PKB has recently emerged as an important mediator of a variety of cancerassociated effects of c-erbB2 signaling, including desensitization to tumourpreventing mechanisms such as cell cycle arrest by p21 WAF (Zhou et al., 2001) , hormone-dependence (Wen et al., 2000) and TNF-induced apoptosis (Zhou et al., 2000) . Since impairment of α 2 β 1 integrin-mediated adhesion has been strongly associated with breast cancer progression (Zutter et al., 1990; Zutter et al., 1995) , the results of the present study may present yet another aspect of PKB function in c-erbB2-induced carcinogenesis. The influence of integrin inactivation on the emerging carcinoma cell is likely to include increased motility and ivasiveness, facilitating tumor cell dissemination and metastasis. This process would be further enhanced by the recently identified PKB-mediated matrix metalloproteinase production (Kim, 2001 Antibody-mediated activation of integrin α 2 β 1 restores adhesion in NGF-treated HB2/tnz34 cells. Cells were pre-treated for 1h with the antibodies HAS4 (10 µg/ml), TS2/16 (0.5 µg/ml) or JBS2 (10 µg/ml), which activate integrin α 2 , β 1 or α 2 β 1 , respectively, before incubation with or without 50 ng/ml NGF as indicated.
(D) Effect of cytochalasin D treatment on adhesion of HB2/tnz34 cells to collagen.
Cells were pre-treated for 1 h with or without 10 nM cytochalasin D followed by treatment with NGF (50 ng/ml), TS2/16 (0.5 µg/ml) or neither for 1 h. 
